ARTICLE | Clinical News
TD139: Ph IIa data
March 17, 2017 1:02 PM UTC
Data from 24 patients with IPF in the Phase IIa portion of a double-blind, placebo-controlled, U.K. Phase Ib/IIa trial showed that once-daily inhaled TD139 for 2 weeks was well tolerated. Additional d...
BCIQ Company Profiles
BCIQ Target Profiles